Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
作者: Sinead ToomeyAlexander J. EustaceJoanna FayKatherine M. SheehanAoife CarrMalgorzata MilewskaStephen F. MaddenAusra TeiserskieneElaine W. KayNorma O’DonovanWilliam GallagherLiam GroganOscar BreathnachJanice WalsheCatherine KellyBrian MoultonM. John KennedyGuiseppe GulloArnold D. HillColm PowerDeirdre DukeNiamh HamblyJohn CrownBryan T. Hennessy
作者单位: 1Royal College of Surgeons in Ireland
2Cancer Trials Ireland
3Dublin City University
4University College Dublin
5Beaumont Hospital
6St. Vincent’s University Hospital
7The Mater Misericordiae University Hospital
8St. James Hospital
9Royal College of Surgeons In Ireland
刊名: Breast Cancer Research, 2017, Vol.19 (1)
来源数据库: Springer Nature Journal
DOI: 10.1186/s13058-017-0883-9
关键词: Breast cancerHER2TrastuzumabLapatinibPI3K pathwaySomatic mutations
英文摘要: The Cancer Genome Atlas analysis revealed that somatic EGFR , receptor tyrosine-protein kinase erbB-2 ( ERBB2 ), Erb-B2 receptor tyrosine kinase 3 ( ERBB3 ) and Erb-B2 receptor tyrosine kinase 4 ( ERBB4 ) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit ( PIK3CA ) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Because ERBB family mutations can activate the PI3K/AKT pathway and likely have similar canonical signalling effects to PI3K pathway mutations, we investigated their combined impact on response to neoadjuvant HER2-targeted therapies.
原始语种摘要: The Cancer Genome Atlas analysis revealed that somatic EGFR , receptor tyrosine-protein kinase erbB-2 ( ERBB2 ), Erb-B2 receptor tyrosine kinase 3 ( ERBB3 ) and Erb-B2 receptor tyrosine kinase 4 ( ERBB4 ) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit ( PIK3CA ) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Because ERBB family mutations can activate the PI3K/AKT pathway and likely have similar canonical signalling effects to PI3K pathway mutations, we investigated their combined impact on response to neoadjuvant HER2-targeted therapies.
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:5.872 (2012)

×
关键词翻译
关键词翻译
  • somatic 躯体的
  • targeted 对准目标的
  • family 
  • positive 阳片
  • pathway 轨道
  • breast 胸部
  • likely 大概
  • tyrosine 酪氨酸
  • receptor 接受体
  • kinase 激酶